The Center for Rheumatology has performed nearly 100 trials of clinical interventions for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis since our founding in October of 2000. These trials have enabled our patients to participate in cutting-edge clinical research. Medications studied at TCFR, prior to their approval, include several of the agents now helping patients with RA throughout the world including Enbrel, Orencia, Actemra, and Xeljanz for RA and Cosentyx for Psoriatic Arthritis. Several other soon to be approved drugs have also been offered to our patients.

We are presently conducting several trials on drugs for the following conditions: RA, Spondyloarthritis and Psoriatic Arthritis.  Dr. Joel M. Kremer, the Director of Research, has published widely on these and other interventions including methotrexate and is a frequent contributor to national and international meetings on treatments and their side effects.  Since joining the practice from Albany Medical College at the time of its founding, Dr. Kremer and his dedicated research staff of outstanding professionals treat every study participant with the care and respect they deserve and are a major reason for our research success. It is with pleasure that we offer our experience and expertise and provide these opportunities for research participation.

 If you are interested in participation in a research trial please contact The Center for Rheumatology and we can provide details.